All In Biotech

Investigational drug · Phase 3

dabocemagene autoficel

Also called: FCX-007, see below for FCX-007 description

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recessive Dystrophic Epidermolysis Bullosa.

Phase 3

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "dabocemagene autoficel"

First trial start

2020

Jun 9, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "dabocemagene autoficel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Recessive Dystrophic Epidermolysis Bullosa

Approved drugs for the same conditions: Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "dabocemagene autoficel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Recessive Dystrophic Epidermolysis Bullosa

  • KB803Phase 31 trial

    Krystal Biotech, Inc. · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa

  • pz-celEB-101 Surgical application of RDEB woundsPhase 31 trial

    Abeona Therapeutics, Inc · Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.